Regulatory T cells are essential guardians against autoimmune disease. They suppress excessive immune reactions and help prevent the body from attacking its own tissues. Inside tumors, however, that same suppressive function can become an advantage for malignant cells. Ti-Treg cells accumulate in the tumor microenvironment and restrain immune activity that might otherwise destroy cancer cells. Their behavior is shaped not only by immune signals but also by the unusual metabolism of tumors, where oxygen can be scarce and nutrients are unevenly distributed. Tumor cells and surrounding stromal cells commonly release large amounts of lactate, a product of glucose metabolism. Rather than serving merely as metabolic waste, lactate can act as a signaling and regulatory molecule. The new findings suggest that Ti-Treg cells exploit this lactate-rich setting to reprogram their own metabolism and acquire the ability to undermine NK-cell function.

The central enzyme identified in the study is glutamate dehydrogenase 1, or GDH1. This enzyme helps regulate the conversion of glutamate into α-ketoglutarate, a metabolite that participates in the tricarboxylic acid cycle and also influences gene regulation. The researchers found that Ti-Treg cells increase GDH1 expression, resulting in higher levels of α-ketoglutarate. That metabolic shift was associated with accelerated tumor progression. α-ketoglutarate is especially important because it can serve as a cofactor for a family of enzymes that chemically modify proteins and nucleic acids. In this case, the metabolite fuels activity linked to ALKBH5, an RNA demethylase. By connecting a change in cellular metabolism to the stability or expression of a specific immune-regulatory gene, the study provides a mechanistic explanation for how the tumor environment can reshape immune-cell behavior from the inside out.

The pathway begins with lactate entering Ti-Treg cells through SLC16A1, a transporter that moves monocarboxylates such as lactate across the cell membrane. Within the lactate-rich tumor microenvironment, the researchers found that GDH1 undergoes lactylation, a chemical modification associated with the presence of lactate. This modification boosts GDH1’s ability to generate α-ketoglutarate. The result is a metabolic circuit in which lactate does not simply provide fuel: it changes the activity of an enzyme, increases a regulatory metabolite and ultimately alters gene expression. The chain can be summarized as lactate uptake, GDH1 lactylation, increased α-ketoglutarate production and enhanced ALKBH5-dependent regulation of Wnt2. Each step offers a possible point of intervention. It also illustrates why cancer metabolism is increasingly viewed as an information system as well as an energy system, capable of transmitting signals between the tumor and immune cells.

The gene Wnt2 encodes a member of the WNT family, a group of secreted signaling proteins involved in communication between cells, tissue development and cancer biology. In the Ti-Treg cells examined in the study, the lactate-driven α-ketoglutarate increase fuels ALKBH5-mediated control of Wnt2 expression. The resulting increase in WNT2 affects neighboring NK cells. NK cells normally recognize and eliminate stressed, infected or transformed cells without requiring the same antigen-specific priming used by conventional T cells. They can release cytotoxic molecules, including perforin and granzymes, that damage target cells. But in the tumor microenvironment, their activity can deteriorate. The study links WNT2 produced under the influence of Ti-Treg metabolism to NK-cell senescence, a state in which cells lose functional capacity and may no longer mount an effective antitumor response.

Senescence is not simply temporary exhaustion. A senescent cell undergoes a durable change in its biological state, often involving altered gene expression, reduced proliferation and changes in the signals it sends to neighboring cells. For NK cells, senescence can mean diminished ability to kill tumor cells and reduced effectiveness after transfer into a patient or experimental host. By inducing this state, Ti-Treg cells can neutralize an immune population that cancer therapies are designed to mobilize. The findings therefore reveal an indirect form of immune suppression: Ti-Treg cells do not merely inhibit NK cells through conventional suppressive signals, but use a metabolic pathway to produce WNT2 and push NK cells toward functional decline. This distinction matters because it suggests that an apparently resistant tumor may not be protecting itself only through cancer-cell mutations or checkpoint signals. It may also be constructing a metabolic environment that ages immune cells before they can attack.

The researchers tested whether interrupting the circuit could restore antitumor immunity. Inhibition of GDH1 reduced the metabolic activity associated with the pathway, while deletion of SLC16A1 specifically in Ti-Treg cells limited lactate uptake. Both interventions reduced NK-cell senescence, according to the study. The results place lactate transport and GDH1 activity upstream of the changes observed in NK cells, strengthening the case that the pathway is causal rather than merely a correlation between tumor metabolism and immune dysfunction. Importantly, interfering with the circuit also improved adoptive NK-cell transfer therapy. In this approach, NK cells are supplied from outside the tumor in an effort to increase the number of cancer-killing immune cells. The study suggests that adding more NK cells may not be enough if Ti-Treg cells continue to expose them to the lactate–α-ketoglutarate–WNT2 circuit. Protecting transferred cells from that environment could substantially improve their therapeutic performance.

The work also highlights the challenge of targeting metabolism without damaging beneficial immune regulation. GDH1 is not unique to Ti-Treg cells, and lactate transporters are used by many normal cells. A broadly acting drug could therefore produce unwanted effects if it disrupts essential metabolic processes in healthy tissues or alters regulatory T-cell activity throughout the body. The most selective strategy suggested by the findings would be to target the pathway within tumor-infiltrating Treg cells, block their access to lactate, or interfere with the GDH1 modification that specifically amplifies α-ketoglutarate production in the tumor setting. Another possibility would be to prevent the downstream WNT2 signal from acting on NK cells. Each approach raises different pharmacological and safety questions. The source study establishes the circuit and identifies intervention points, but translating those findings into treatment will require determining how broadly the mechanism operates across tumor types and how it interacts with existing immunotherapies.

The discovery could be particularly relevant to efforts to improve cell-based cancer treatments, which often fail because transferred immune cells become dysfunctional after entering a tumor. Adoptive NK-cell therapy is attractive because NK cells can recognize malignant stress signals and kill targets without the individualized antigen matching required for some T-cell therapies. Yet their effectiveness depends on surviving and remaining active inside the tumor microenvironment. The new study suggests that Ti-Treg cells may act as metabolic gatekeepers, converting a tumor’s excess lactate into a signal that disables incoming NK cells. Blocking SLC16A1, GDH1 or the downstream WNT2 pathway could therefore be explored as a combination strategy rather than as a standalone treatment. Such combinations might include NK-cell transfer, immune checkpoint blockade or other approaches designed to increase immune-cell infiltration. Whether the mechanism is shared by human tumors remains an important question, as does the possibility that related metabolic circuits suppress other immune-cell types.

At a broader level, the study reframes the relationship between cancer metabolism and immune suppression. Lactate has often been associated with poor immune performance because of its effects on acidity and cellular energy balance. The findings describe a more specific and sophisticated process: lactate chemically modifies GDH1 in Ti-Treg cells, raises α-ketoglutarate, engages an RNA-regulatory enzyme and increases WNT2 production, which then promotes NK-cell senescence. That sequence connects a metabolite, an enzyme modification, epigenetic or RNA regulation and intercellular immune signaling in a single pathway. The researchers’ identification of GDH1 inhibition and Ti-Treg-specific SLC16A1 deletion as ways to reduce NK senescence provides a foundation for therapeutic investigation. If future studies confirm the circuit in human cancers, disrupting this metabolic relay could help turn the tumor microenvironment from a place that exhausts immune cells into one where transferred and naturally occurring NK cells retain their ability to attack malignant tissue.

TRAILshort is an alternatively spliced form of the TRAIL gene. The best-known TRAIL proteins participate in programmed cell death, a process through which immune cells eliminate infected or malignant cells. TRAILshort, however, has a distinct structure and biological behavior. Mayo Clinic scientists first identified it while investigating HIV nearly 15 years ago, and later found that cancer cells can also produce it. Until now, its precise effect on immune signaling had remained unclear. The new research shows that TRAILshort does more than interfere with cell death: it directly disrupts the signaling machinery that allows T cells to recognize and respond to danger.

T cells rely on the T-cell receptor, or TCR, to detect molecular fragments displayed by infected or abnormal cells. Once the receptor is engaged, a chain of phosphorylation events activates signaling proteins that reorganize the cell, promote cytokine production and enable the T cell to kill its target. The Mayo Clinic team found that TRAILshort interrupts this process by activating SHP-1, a protein tyrosine phosphatase. SHP-1 removes phosphate groups from key signaling molecules, effectively applying a biochemical brake before the T cell can complete its activation program.

The result is a form of immune tolerance that benefits diseased cells. When TRAILshort levels are elevated, T cells may encounter cancer cells or infected cells but fail to generate a sufficiently strong response. This mechanism was detected in melanoma, lung, breast, pancreatic and ovarian cancers, as well as Hodgkin lymphoma. Elevated TRAILshort was also associated with infectious diseases including HIV, COVID-19, tuberculosis and hepatitis C. The broad distribution of the protein suggests that it may represent a shared pathway of immune dysfunction rather than a mechanism restricted to a single tumor type or pathogen.

The researchers used highly specific antibodies and engineered preclinical models to examine the protein’s activity. When TRAILshort was blocked, T cells regained signaling capacity and showed improved functional responses against diseased cells. These findings are significant because immune failure in cancer and chronic infection is often attributed to a combination of suppressive signals within the tissue environment. TRAILshort appears to be one of those signals, acting at an early stage of T-cell receptor signaling and potentially preventing immune cells from entering a fully active state.

The study also examined chimeric antigen receptor T-cell therapy, or CAR-T therapy. In this treatment, a patient’s T cells are genetically modified to express synthetic receptors that recognize specific cancer-associated molecules. Although CAR-T therapy can produce durable remissions in some blood cancers, its effectiveness can be limited when tumor cells create an immunosuppressive environment. In preclinical experiments, TRAILshort reduced the ability of CAR-T cells to control tumors. Removing or blocking the protein restored CAR-T activity, indicating that TRAILshort may be an important barrier to the success of cellular immunotherapies.

A therapy directed against TRAILshort could therefore be used alongside CAR-T cells, immune checkpoint inhibitors or other treatments designed to activate antitumor immunity. The protein might also serve as a biomarker. Tumors with high TRAILshort expression could be more likely to resist immune-based treatments, while patients whose tumors show lower levels might respond differently. Before such applications can be considered in humans, researchers will need to determine how TRAILshort is produced, how it moves through the tumor microenvironment and whether blocking it causes excessive inflammation or autoimmune complications.

The mechanism may also be relevant to viral disease. Chronic infections such as HIV and hepatitis C can drive prolonged immune stimulation, followed by T-cell exhaustion and functional decline. During COVID-19 and tuberculosis, immune regulation can become similarly unbalanced, with inadequate pathogen control in some patients and damaging inflammation in others. Because TRAILshort appears in several of these conditions, researchers are investigating whether it contributes to a common pattern of immune suppression. If so, carefully timed TRAILshort inhibition could potentially strengthen antiviral or antimicrobial responses, although such an approach would require precise control to avoid worsening immunopathology.

The same biology could have an opposite therapeutic use in autoimmune disease and transplantation. In cancer and persistent infection, researchers may seek to reduce TRAILshort activity and release the brake on T cells. In lupus, Crohn’s disease or transplant rejection, increasing TRAILshort activity could theoretically dampen harmful immune responses without broadly suppressing the immune system. This two-directional strategy remains experimental, and additional studies are needed to establish whether the protein can be safely manipulated in patients. The discovery nevertheless provides a defined molecular target for regulating T-cell behavior across cancer, infection and immune-mediated disease.

Subject of Research: TRAILshort-mediated suppression of T-cell signaling in cancer, viral infection and immune-related diseases.

Article Title: TRAIL splice variant TRAILshort disrupts T cell receptor signaling and promotes immune tolerance in vivo

Web References: Mayo Clinic; Journal of Clinical Investigation: https://www.jci.org/articles/view/194449

References: Journal of Clinical Investigation, “TRAIL splice variant TRAILshort disrupts T cell receptor signaling and promotes immune tolerance in vivo,” published 3 August 2026.

Keywords: TRAILshort, T cells, T-cell receptor signaling, SHP-1, cancer immunotherapy, CAR-T therapy, viral infections, HIV, COVID-19, tuberculosis, immune tolerance, Mayo Clinic

Myeloid-derived suppressor cells have long been recognized as potent regulators of immune responses, especially in pathological contexts such as tumor microenvironments where they inhibit the activity of cytotoxic T cells, aiding cancer progression. Despite extensive research, the molecular underpinnings that govern MDSC differentiation and functionality have remained elusive. This latest research shines a spotlight on MARCO (macrophage receptor with collagenous structure), a surface receptor expressed on subsets of myeloid cells, revealing its indispensable contribution to these processes.

The investigators utilized a combination of in vitro cell culture systems, genetic manipulation techniques, and murine models to dissect the role MARCO plays at various stages of MDSC biology. Through targeted knockdown and gene-editing approaches, the study demonstrated that the absence of MARCO led to a marked impairment in MDSC differentiation from their myeloid progenitors. Furthermore, MDSCs devoid of MARCO expression exhibited a significant reduction in their ability to suppress T cell proliferation and cytokine production, underscoring the receptor’s pivotal role in sustaining immunosuppression.

At a mechanistic level, the research shows that MARCO signaling influences several key intracellular pathways related to cell survival, differentiation, and immunomodulatory molecule production. MARCO-expressing MDSCs displayed upregulated expression of critical immunosuppressive mediators such as arginase-1, inducible nitric oxide synthase (iNOS), and transforming growth factor-beta (TGF-β), all known for their capacity to dampen effective immune responses. This molecular signature, absent or diminished in MARCO-deficient cells, highlights how MARCO facilitates the establishment of the immunosuppressive phenotype.

Remarkably, the study also unveiled that MARCO interaction with its ligands enhances the recruitment of MDSCs to tumor sites. This trafficking function, mediated by receptor-ligand binding and downstream signaling cascades, effectively potentiates the tumor’s ability to evade immune surveillance. Through sophisticated imaging analyses and flow cytometry, the authors confirmed a significantly reduced tumor infiltration by MDSCs lacking MARCO, correlating with improved anti-tumor immunity in experimental models.

In addition to insights into cancer biology, this research carries implications for infectious diseases as well. Given the role of MDSCs in chronic infections—where they prevent excessive tissue damage by suppressing overactive immune responses—the study suggests that MARCO could be a double-edged sword. While its expression on MDSCs helps maintain immune homeostasis and prevent collateral damage, overactivation might contribute to persistent infection or disease progression by excessively dampening host immunity.

Therapeutically, targeting MARCO presents a promising yet complex prospect. The researchers caution that while inhibiting MARCO function in MDSCs could unleash potent anti-tumor immune responses, it may simultaneously increase the risk of hyperinflammation or autoimmunity. Hence, future interventions would need to fine-tune this balance carefully. The identification of MARCO as a decisive factor in MDSC biology provides a much-needed molecular handle to achieve such precision.

Beyond the functional implications, the study enhances fundamental immunology by elucidating how innate immune receptors like MARCO interface with the differentiation programs of suppressive myeloid cells. It adds a layer of clarity to the heterogeneous landscape of MDSCs, which include diverse subsets with distinct molecular profiles and functional capacities. By pinpointing MARCO as a defining marker of immunosuppressive competence, the researchers offer a novel biomarker that could be leveraged for diagnostic or prognostic purposes.

Methodologically, the use of advanced genetic editing techniques, including CRISPR-Cas9 mediated knockout models, lent robustness and specificity to the findings. Coupled with detailed flow cytometric analysis and transcriptomic profiling, the study paints a comprehensive picture of how MARCO modulates cellular phenotypes and responses. These innovative approaches set a benchmark for future investigations into the molecular regulation of immune suppressor cells.

Furthermore, exploration of MARCO’s ligand interactions revealed intriguing possibilities regarding extracellular matrix components or pathogen-associated molecules as modulators of MDSC function. This aligns with the known pattern recognition capabilities of scavenger receptors, which detect diverse ligands to initiate appropriate cellular responses. Understanding these ligand-receptor dynamics could broaden therapeutic strategies to manipulate MDSC activity in disease contexts.

The translational potential of this discovery is underscored by ongoing efforts to develop MARCO-targeted antibodies or small molecule inhibitors that could selectively modulate MDSC populations. Such agents may synergize with checkpoint inhibitors or other immunotherapies, enhancing their efficacy in cancer treatment. Conversely, MARCO agonists might be explored to boost MDSC-mediated protection in autoimmune or inflammatory diseases, illustrating the wide-reaching impact of this receptor beyond oncology.

In the broader perspective of immune modulation, the elucidation of MARCO’s role challenges the traditional dichotomy between immune activation and suppression, highlighting a nuanced regulatory framework involving receptor-mediated fine-tuning of cellular differentiation and function. This paradigm shift may inspire new conceptual models for the immune system’s adaptability in health and disease.

Looking ahead, questions remain regarding the upstream signals that regulate MARCO expression on MDSCs and how these pathways interplay with other immunoregulatory networks. Additionally, investigation into MARCO’s role in human MDSCs, as opposed to murine models, will be critical to translate these findings into clinical applications. The heterogeneity within human myeloid compartments presents both challenges and opportunities for this line of research.

In conclusion, the study by Liu and colleagues offers a compelling narrative about the indispensable role of MARCO in dictating the fate and function of myeloid-derived suppressor cells. By integrating molecular, cellular, and in vivo analyses, the research advances our grasp of immune suppression mechanisms and brings us closer to tailored immunotherapeutic interventions. The potential to manipulate MDSC dynamics via MARCO may herald a new era in the treatment of cancer and immune-related disorders, where precision modulation of immune cells determines therapeutic success.

As the field moves forward, the translation of these insights into clinical practice will require multidisciplinary efforts combining immunology, oncology, pharmacology, and bioengineering. Nonetheless, this landmark discovery solidifies MARCO as a linchpin in immunoregulation and a promising beacon for future biomedical innovation.

Subject of Research: The role of MARCO expression on myeloid-derived suppressor cells (MDSCs) in regulating their differentiation and immunosuppressive function.

Article Title: MARCO expression on myeloid-derived suppressor cells is essential for their differentiation and immunosuppression.

Article References:
Liu, S., Tian, B., Wang, N. et al. MARCO expression on myeloid-derived suppressor cells is essential for their differentiation and immunosuppression. Cell Death Discov. 11, 337 (2025). https://doi.org/10.1038/s41420-025-02627-1

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41420-025-02627-1